Versamet Royalties Corporation ( VMET:CA ) said on Wednesday it has amended and upsized its revolving credit facility to $225 million and repaid its existing term loan. The amended facility includes a $200 million secured revolving credit line and an accordion feature allowing for an additional $25 million, subject to certain conditions. The facility matures in March 2029. The new arrangement repl...
Versamet Royalties Corporation ( VMET:CA ) said on Wednesday it has amended and upsized its revolving credit facility to $225 million and repaid its existing term loan. The amended facility includes a $200 million secured revolving credit line and an accordion feature allowing for an additional $25 million, subject to certain conditions. The facility matures in March 2029. The new arrangement replaces the company’s previous $100 million revolving credit facility and $80 million term loan, which has been fully repaid. As of March 4, 2026, $45 million was drawn under the facility. Pricing remains unchanged and is based on a sliding scale ranging from 2.25% to 3.50% over adjusted SOFR, depending on the company’s leverage ratio. VMET:CA closed +0.38% at $13.0. Source: Press Release More on Versamet Royalties Corporation Seeking Alpha’s Quant Rating on Versamet Royalties Corporation Historical earnings data for Versamet Royalties Corporation Financial information for Versamet Royalties Corporation
The Global Race To Unlock Nuclear Fusion Authored by Felicity Bradstock via oilprice.com , Governments worldwide have been racing to unlock the secret to nuclear fusion energy for several decades, with the aim of producing abundant, clean energy. While several generation milestones have been achieved in recent years, accomplishing commercial-scale production continues to be extremely complex. Howe...
The Global Race To Unlock Nuclear Fusion Authored by Felicity Bradstock via oilprice.com , Governments worldwide have been racing to unlock the secret to nuclear fusion energy for several decades, with the aim of producing abundant, clean energy. While several generation milestones have been achieved in recent years, accomplishing commercial-scale production continues to be extremely complex. However, with more recent successes, are we edging closer to achieving this goal and producing vast quantities of clean power? Nuclear fusion is the process that powers the sun and stars . Fusion takes place when two atomic nuclei – typically formed of hydrogen – are combined into a heavier nucleus, which releases a large quantity of energy. The difficulty in achieving this process is that scientists must recreate extreme temperatures and pressures that cause fusion in stars on Earth. By contrast, nuclear fission – the method currently used to produce nuclear power – occurs when the central core of an atom, known as the nucleus, of uranium or plutonium, splits into two smaller nuclei . Splitting the core results in the release of a large amount of energy and the creation of additional neutrons, which can go on to split more atoms in a chain reaction. The chain reaction allows nuclear reactors to produce a stable supply of energy. Fusion energy is extremely attractive as it could provide massive amounts of clean power at a time when the electricity demand is soaring. Just one gramme of fusion fuel could supply 90,000 kilowatt-hours of energy in a power plant, compared to the power produced from around 11 tonnes of coal. Fusion plants are also viewed as very safe, as they do not have the same risks as in fission plants , such as reactions, meltdowns or high-level, long-lived radioactive waste. This also means that fusion facilities may be easier to gain licenses for than fission plants. In recent years, advancements in the generation of fusion power have mainly been seen in the p...
Late in 2025, we covered the development of an AI system called Evo that was trained on massive numbers of bacterial genomes. So many that, when prompted with sequences from a cluster of related genes, it could correctly identify the next one or suggest a completely novel protein. That system worked because bacteria tend to cluster related genes together—something that's not true in organisms with...
Late in 2025, we covered the development of an AI system called Evo that was trained on massive numbers of bacterial genomes. So many that, when prompted with sequences from a cluster of related genes, it could correctly identify the next one or suggest a completely novel protein. That system worked because bacteria tend to cluster related genes together—something that's not true in organisms with complex cells, which tend to have equally complex genome structures. Given that, our coverage noted, "It’s not clear that this approach will work with more complex genomes." Apparently, the team behind Evo viewed that as a challenge, because today it is describing Evo 2, an open source AI that has been trained on genomes from all three domains of life (bacteria, archaea, and eukaryotes). After training on trillions of base pairs of DNA, Evo 2 developed internal representations of key features in even complex genomes like ours, including things like regulatory DNA and splice sites, which can be challenging for humans to spot. Read full article Comments
"These are good numbers," Gil Luria, head of technology research at D.A. Davidson, says about Broadcom's first-quarter earnings and revenue guidance. He speaks on "Bloomberg The Close." (Source: Bloomberg)
"These are good numbers," Gil Luria, head of technology research at D.A. Davidson, says about Broadcom's first-quarter earnings and revenue guidance. He speaks on "Bloomberg The Close." (Source: Bloomberg)
Earnings Call Insights: Nexxen International Ltd. (NEXN) Q4 2025 Management View CEO Ofer Druker stated that Nexxen "met our updated full year guidance and are seeing strong momentum in early 2026," highlighting record January and February performance. Druker attributed this to "infrastructure investments made in 2025 to support long-term programmatic trading growth" and new partnerships with lead...
Earnings Call Insights: Nexxen International Ltd. (NEXN) Q4 2025 Management View CEO Ofer Druker stated that Nexxen "met our updated full year guidance and are seeing strong momentum in early 2026," highlighting record January and February performance. Druker attributed this to "infrastructure investments made in 2025 to support long-term programmatic trading growth" and new partnerships with leading DSPs, especially in CTV and enterprise solutions. He emphasized the launch of the "industry's first programmatic Smart TV on screen advertising solution" with VI (formerly VIDAA) and The Trade Desk, describing it as "a pivotal milestone in expanding high-quality programmatic advertising on the open Internet through a new engaging channel that is more resistant to AI-driven disruption." Druker also discussed broadening AI integration: "Customers are achieving better results with less effort while unlocking new capabilities," citing DSP assistant efficiency gains of up to 97% and satisfaction scores over 90%. He noted a more than doubling of the enterprise customer base in 2025. CFO Sagi Niri reported, "contribution ex-TAC and programmatic revenue to date in Q1 are trending ahead of our initial expectations," and described a positive spending trend by a previously cautious DSP customer. Niri explained, "In Q4, we delivered contribution ex-TAC of $97.8 million, reflecting a 7% year-over-year decrease or a 1% decrease ex political. Programmatic revenue was $94.3 million, down 4% year-over-year, but up 2% ex political." He also noted a 19% year-over-year decline in CTV revenue, but signaled confidence in a rebound: "We feel well positioned for CTV revenue growth in 2026 and beyond." Niri highlighted a share repurchase of 1.44 million shares in Q4 and an approved new buyback program of up to $40 million. He confirmed Nexxen's continued investments in VI, aiming for a 6% equity stake after an additional $15 million investment in Q3 2026. Outlook For full year 2026, Nexxen expe...
Earnings Call Insights: EyePoint, Inc. (EYPT) Q4 2025 Management View Jay Duker, President and CEO, stated that “2025 was defined by significant progress and achievement for EyePoint as we made important advances that set the stage for success and potential value creation for the year ahead.” He highlighted that DURAVYU is on track to deliver top line data in wet AMD beginning in mid-2026 and that...
Earnings Call Insights: EyePoint, Inc. (EYPT) Q4 2025 Management View Jay Duker, President and CEO, stated that “2025 was defined by significant progress and achievement for EyePoint as we made important advances that set the stage for success and potential value creation for the year ahead.” He highlighted that DURAVYU is on track to deliver top line data in wet AMD beginning in mid-2026 and that first patients were dosed in both pivotal Phase III DME trials. Duker also emphasized a strong cash position expected to fund operations into Q4 2027 and described the ongoing transition to a commercial organization with the appointment of Michael Campbell as Chief Commercial Officer. Duker outlined that DURAVYU’s clinical profile is “compelling,” citing durability, improved vision, anatomical control, and a favorable safety record in over 190 patients. He also noted that the drug’s unique mechanism, “inhibits VEGF, PDGF and IL-6 via the JAK1 receptor with no TIE-2 inhibition,” which is believed to address both vascular leakage and inflammation in retinal diseases. The company is preparing for regulatory filings, with operations expanding at its Northbridge, Massachusetts cGMP facility and readiness for pre-approval inspection. George Elston, Executive VP & CFO, stated, “We ended 2025 with a strong balance sheet of $306 million in cash and investments, driven by continued stewardship of our resources and $173 million follow-on financing in October.” Outlook Duker indicated that EyePoint expects to report top line data for the Phase III LUGANO trial in mid-2026 with LUCIA data to follow closely, complete enrollment in the pivotal Phase III DME program in the second half of 2026, and prepare for regulatory filing in wet AMD, assuming positive data. The company plans to fund operations into the fourth quarter of 2027, covering key milestones including NDA preparation for the wet AMD program and fully funding the DME program. Financial Results Elston reported total net revenue...
tirc83 Cracker Barrel Old Country Store ( CBRL ) rallied in Wednesday’s after-hours trading after delivering a less-than-expected top- and bottom-line miss and narrowing its FY26 sales forecast. Shares were up more than 9% after the closing bell. “Our disciplined focus on operational excellence is driving significant improvements in several key guest metrics, many of which serve as important leadi...
tirc83 Cracker Barrel Old Country Store ( CBRL ) rallied in Wednesday’s after-hours trading after delivering a less-than-expected top- and bottom-line miss and narrowing its FY26 sales forecast. Shares were up more than 9% after the closing bell. “Our disciplined focus on operational excellence is driving significant improvements in several key guest metrics, many of which serve as important leading traffic indicators. We have also taken additional actions to improve financial performance and remain confident that we are well-positioned to regain prior momentum," CEO Julie Masino said in response to the FQ2 results. The company generated $874.8M in revenue during the quarter, down 8% from a year earlier, as comparable restaurant sales were down 7.1% and comparable store retail sales decreased 9.2%. This, however, compares to estimates for a deeper cut in sales to $864.35M. Adjusted earnings of $0.25 per share were down from $1.38 a year ago but much better than expectations for a loss of $0.30 per share. Adjusted EBITDA was down as well, declining by nearly 50% to $38.2M. For FY26, Cracker Barrel ( CBRL ) expects to generate revenue between $3.24B and $3.27B versus a prior outlook of $3.2B and $3.3B, with a new midpoint of $3.255B that is slightly above $3.25B estimates. Adjusted EBITDA is now expected to be between $85M and $100M versus the previous outlook of $70M to $110M, and commodity inflation of 2% to 2.5% from 2.5% to 3.5% prior. The company also said it plans to invest $105M to $115M, less than the initial outlook for an investment of $110M to $125M. More on Cracker Barrel Cracker Barrel: From 'Front Porch' To Basement, Is It A Buy? Cracker Barrel's Still Trying To Get Customers To Come Back Cracker Barrel: Comp Sales Are Getting Crushed (Downgrade) Cracker Barrel Q2 2026 Earnings Preview Small-cap stocks with lowest dividend growth grade
Coroner suggested Hajra, 29, and Haleema Zahid, 25, who could not swim, may have slipped into pools on path up Snowdon Two sisters have accidentally drowned after they paddled fully clothed at a national park beauty spot in Wales, an inquest has heard. Hajra Zahid, 29, and her sibling Haleema, 25, were pulled from pools on the Watkin Path, which leads to the Snowdon mountain summit. Both visited t...
Coroner suggested Hajra, 29, and Haleema Zahid, 25, who could not swim, may have slipped into pools on path up Snowdon Two sisters have accidentally drowned after they paddled fully clothed at a national park beauty spot in Wales, an inquest has heard. Hajra Zahid, 29, and her sibling Haleema, 25, were pulled from pools on the Watkin Path, which leads to the Snowdon mountain summit. Both visited the picturesque wild swimming site and its waterfall at Eryri (Snowdonia) national park, in the Nant Gwynant area of Gwynedd, on 11 June 2025 with three male friends. The group of five, who were all students at the University of Chester, split up for privacy and religious reasons as the sisters, who could not swim, headed for a pool upstream on the Afon Cwm Llan river. The men later called out for the sisters, from Rotherham in South Yorkshire, but got no reply to their shouts and when they reached the pools they noticed their shoes and personal belongings at the side. They later discovered Hajra, a married mother-of-two, floating face down in her red dress. Caernarfon coroner’s court was told they managed to pull an unconscious Hajra on to the riverbank but they were unable to find Haleema. Emergency services were called and two members of Llanberis mountain rescue team later retrieved Haleema, who was wearing blue jeans and a black shirt, from deep water near the waterfall. Shortly after both women were pronounced dead at the scene. The assistant coroner for north-west Wales, Sarah Riley, said she found that the sisters had intended to paddle in the water. She said: “Having considered the evidence that neither could swim and that they were fully clothed I am satisfied that neither sister went to swim or enter parts of the pool that would put them out of their depths in the water.” She said one possibility was that one or both had fallen from an “exceptionally slippy” slab of rock at the edge of the pools. The inquest heard the mountain team rescuers who entered the water h...
KKR Co-CEO, Scott Nuttall discusses the firm’s evolution into a diversified global investment platform and its dealmaking priorities with Bloomberg’s Dani Burger at Bloomberg Invest 2026 in New York. (Source: Bloomberg)
KKR Co-CEO, Scott Nuttall discusses the firm’s evolution into a diversified global investment platform and its dealmaking priorities with Bloomberg’s Dani Burger at Bloomberg Invest 2026 in New York. (Source: Bloomberg)
Viemed Healthcare ( VMD ) said on Wednesday its board authorized a share repurchase program effective through March 2027. Under the program, the company may repurchase up to 1,930,131 common shares, representing about 5% of its issued and outstanding shares as of March 4, 2026. The repurchases may be made through open market or block purchases, or otherwise in accordance with applicable securities...
Viemed Healthcare ( VMD ) said on Wednesday its board authorized a share repurchase program effective through March 2027. Under the program, the company may repurchase up to 1,930,131 common shares, representing about 5% of its issued and outstanding shares as of March 4, 2026. The repurchases may be made through open market or block purchases, or otherwise in accordance with applicable securities laws, including Rule 10b-18 under the Securities Exchange Act of 1934. Daily purchases, subject to certain exceptions, will be limited to 25% of the average daily trading volume over the preceding four calendar weeks. The company said there is no assurance as to the number of shares that will be repurchased and that purchases may be discontinued at any time. Shares bought under the program will be cancelled. VMD +1.98% after hours to $9.26. Source: Press Release More on Viemed Healthcare Viemed Healthcare: Remaining Bullish On Keen Valuation And Buoyant Cash Flow Top small-cap healthcare stocks surging above 200-day moving average Seeking Alpha’s Quant Rating on Viemed Healthcare Historical earnings data for Viemed Healthcare Financial information for Viemed Healthcare
The dollar index (DXY00) on Wednesday fell by -0.29%. The dollar was under pressure on Wednesday as stocks rallied on a New York Times report that Iranian operatives made an offer to discuss terms for ending the war. The dollar recovered from its worst level on Wednesday after the Feb ADP employment report showed US employers added more jobs than expected last month, and the Feb ISM services index...
The dollar index (DXY00) on Wednesday fell by -0.29%. The dollar was under pressure on Wednesday as stocks rallied on a New York Times report that Iranian operatives made an offer to discuss terms for ending the war. The dollar recovered from its worst level on Wednesday after the Feb ADP employment report showed US employers added more jobs than expected last month, and the Feb ISM services index unexpectedly expanded by the most in 3.5 years, hawkish factors for Fed policy. The US Feb ADP employment change increased by +63,000, stronger than expectations of +50,000. Join 200K+ Subscribers: The US Feb ISM services index unexpectedly rose +2.3 to 56.1, better than expectations of a decline to 53.5 and the strongest pace of expansion in 3.5 years. The Feb ISM services prices paid sub-index unexpectedly fell -3.6 to an 11-month low of 63.0, weaker than expectations of an increase to 68.3. The Fed Beige Book said that for the period ending February 23, seven of the twelve Fed districts reported that economic activity increased at a slight to moderate pace, with prices rising moderately and employment levels generally stable. Cleveland Fed President Beth Hammack said it's important to drive inflation back to target and that "Fed policy could be on hold for quite some time." Swaps markets are discounting the odds at 4% for a -25 bp rate cut at the next policy meeting on March 17-18. The dollar continues to see underlying weakness as the FOMC is expected to cut interest rates by about -37 bp in 2026, while the BOJ is expected to raise rates by another +25 bp in 2026, and the ECB is expected to leave rates unchanged in 2026. EUR/USD (^EURUSD) on Wednesday rose by +0.23%. The weakness in the dollar on Wednesday supported gains in the euro. Also, Wednesday's Eurozone economic reports, which showed that the Eurozone Jan PPI rose more than expected and the Jan unemployment rate unexpectedly fell to a record low, are hawkish for ECB policy and supportive of the euro. Eurozone J...
April WTI crude oil (CLJ26) on Wednesday closed up +0.10 (+0.13%), and April RBOB gasoline (RBJ26) closed up +0.0575 (+2.34%). Crude oil and gasoline prices settled higher on Wednesday, with gasoline up sharply at a 19.5-month high. Energy prices have been volatile, and on Wednesday, they were whipsawed by headlines. Crude prices initially tumbled on Wednesday on a NY Times report that said Irania...
April WTI crude oil (CLJ26) on Wednesday closed up +0.10 (+0.13%), and April RBOB gasoline (RBJ26) closed up +0.0575 (+2.34%). Crude oil and gasoline prices settled higher on Wednesday, with gasoline up sharply at a 19.5-month high. Energy prices have been volatile, and on Wednesday, they were whipsawed by headlines. Crude prices initially tumbled on Wednesday on a NY Times report that said Iranian operatives made an offer to the US to discuss terms for ending the conflict. However, prices shot higher after Iran denied the report. Wednesday's weekly EIA inventory report was bearish for crude as it showed crude supplies rose more than expected to a 9-month high. Don’t Miss a Day: Crude has some negative carryover from Tuesday, when President Trump said the US will ensure the free flow of energy through the Strait of Hormuz with insurance guarantees and even naval escorts. The closure of the Strait of Hormuz has halted most energy shipments from the Persian Gulf and is bullish for energy prices. Iran's Islamic Revolutionary Guard Corps has warned ships not to sail through the passageway, saying that vessels "could be at risk from missiles or rogue drones." The closure of the Strait of Hormuz, which handles a fifth of the world's oil, has forced Gulf producers unable to export their oil to stockpile the crude in storage tanks. Iraq, OPEC's second-largest producer, shut down oil production at its largest oil fields in Rumalia as storage tanks filled up. Also, Kayrros reported on Wednesday that four of six tanks at Saudi Arabia's Ras Tanura refinery were full, and the Ju'aymah terminal on the country's east coast is quickly running out of spare capacity. Goldman Sachs estimates the real-time risk premium for crude oil at $18/bbl, corresponding to its estimate of the impact of a six-week full halt to tanker traffic in the Strait of Hormuz. Also, damage from an intercepted Iranian drone caused a major fire on Tuesday at the United Arab Emirates' major oil-trading hub, Fuja...
Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to loss of $1.34 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -22.58%. A quarter ago, it was expected that this company would post a loss of $1.26 per share when ...
Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to loss of $1.34 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -22.58%. A quarter ago, it was expected that this company would post a loss of $1.26 per share when it actually produced a loss of $1.41, delivering a surprise of -11.90%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Keros Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $3.04 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 97.11%. This compares to year-ago revenues of $0.14 million. The company has not been able to beat consensus revenue estimates over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Keros Therapeutics shares have lost about 31.1% since the beginning of the year versus the S&P 500's gain of 1.3%. What's Next for Keros Therapeutics? While Keros Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the ...
Verastem (VSTM) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $1.33 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -2.04%. A quarter ago, it was expected that this drug developer would post a loss of $0.51 per share when it actual...
Verastem (VSTM) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $1.33 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -2.04%. A quarter ago, it was expected that this drug developer would post a loss of $0.51 per share when it actually produced a loss of $1.35, delivering a surprise of -164.71%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Verastem, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $17.54 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.20%. This compares to zero revenues a year ago. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Verastem shares have lost about 26.4% since the beginning of the year versus the S&P 500's decline of 0.4%. What's Next for Verastem? While Verastem has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Verastem was mixed. While the magnitude and d...
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Microsoft (NasdaqGS:MSFT) has appointed Asha Sharma as CEO of Microsoft Gaming, following the retirement of Phil Spencer after nearly 40 years at the company. The leadership change is part of a wider executive reshuffle and a re...
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Microsoft (NasdaqGS:MSFT) has appointed Asha Sharma as CEO of Microsoft Gaming, following the retirement of Phil Spencer after nearly 40 years at the company. The leadership change is part of a wider executive reshuffle and a refreshed direction for the gaming division. The transition comes as Microsoft continues integrating Bethesda and Activision Blizzard into its broader gaming ecosystem. For you as an investor watching Microsoft (NasdaqGS:MSFT), the gaming business is one of the company’s key consumer facing pillars, sitting alongside its productivity, cloud and enterprise offerings. The timing of this leadership shift lines up with ongoing work to bring Bethesda and Activision Blizzard fully into Microsoft’s gaming portfolio, including content libraries and distribution platforms. Leadership moves at this level can influence how aggressively Microsoft Gaming approaches content, subscriptions and platform partnerships over the coming years. Asha Sharma’s background in scaling large tech platforms may shape how Microsoft looks at user growth, engagement and monetisation across its gaming ecosystem. Stay updated on the most important news stories for Microsoft by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Microsoft. NasdaqGS:MSFT 1-Year Stock Price Chart Does the team leading Microsoft have what it takes? See our full breakdown of the management team's track record and compensation. This reshuffle in Microsoft Gaming puts product and platform operators at the center of decision making. Asha Sharma comes in with a track record of running large consumer-facing products at Meta and Instacart, which matters when Microsoft Gaming spans consoles, PC, cloud streaming, mobile and large third party franchises like Call of Duty and Candy ...
Bruce Richards, Founder, Chairman & CEO, Marathon Asset Management discusses the macro backdrop, credit markets and investor selectivity with Bloomberg’s Matt Miller at Bloomberg Invest 2026 in New York. (Source: Bloomberg)
Bruce Richards, Founder, Chairman & CEO, Marathon Asset Management discusses the macro backdrop, credit markets and investor selectivity with Bloomberg’s Matt Miller at Bloomberg Invest 2026 in New York. (Source: Bloomberg)
Savaria press release ( SISXF ): Q4 Non-GAAP EPS of $0.37. Revenue of $241.8M (+8.3% Y/Y) beats by $69.01M . More on Savaria Corporation Seeking Alpha’s Quant Rating on Savaria Corporation Historical earnings data for Savaria Corporation Dividend scorecard for Savaria Corporation Financial information for Savaria Corporation
Savaria press release ( SISXF ): Q4 Non-GAAP EPS of $0.37. Revenue of $241.8M (+8.3% Y/Y) beats by $69.01M . More on Savaria Corporation Seeking Alpha’s Quant Rating on Savaria Corporation Historical earnings data for Savaria Corporation Dividend scorecard for Savaria Corporation Financial information for Savaria Corporation